Etanercept in the treatment and retreatment of psoriasis in daily clinical practice.

Etanercept is a tumor necrosis factor alfa (TNFalpha) antagonist whose efficacy and safety in the treatment of psoriasis have been proven in many clinical trials. Nevertheless, few studies evaluate the efficacy and safety of this therapy in patients after discontinuation and readministration. Our study aimed to evaluate the efficacy and safety of etanercept in daily clinical practice for the treatment of patients with moderate-to-severe plaque psoriasis.